This study is looking at how well a combination of treatments works for people with advanced liver cancer (hepatocellular carcinoma or HCC) or metastatic stomach cancer (gastric cancer). You would receive Trans-arterial tirapazamine embolization (TATE), which is a procedure to treat liver tumors, followed by an immune checkpoint inhibitor called nivolumab. Nivolumab helps your body's immune system fight cancer. The study aims to see if TATE can make nivolumab work better. To join, you must be between 18 and 80 years old, have liver lesions, and your cancer must have gotten worse after previous immune therapy. The main goal is to see how many people respond to the treatment, measured over up to 24 months. The current recruitment status is unclear.

Study design

This is an open-label, multi-center Phase IIA study, meaning everyone knows what treatment is being given. It plans to enroll 54 participants.

What's involved

You would receive up to 4 TATE treatments for liver lesions, followed by nivolumab according to its standard schedule until your disease progresses. If your cancer gets worse, you might receive another 2 TATE treatments.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how well the treatment works for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.